The ketamine regulatory environment is what many providers would describe as the “Wild West.” Even with thousands of ketamine clinics opening across the country in the past few years, ketamine therapy providers are still operating in a space defined less by clear regulatory frameworks and more by increasing scrutiny from federal and state authorities. As these models continue to expand, regulators are focusing on applying existing laws to a rapidly evolving treatment landscape. For providers, the question is no longer whether regulators will come knocking, but where regulators are most likely to focus when they do.

In this era of regulatory uncertainty, the providers who are most prepared are in the best position to protect their practices. In this article, we outline how to develop a targeted compliance checklist addressing the core areas already drawing regulators’ attention.

Controlled Substance Compliance

As a Schedule III controlled substance, ketamine is subject to well-established federal requirements governing prescribing, storage, and recordkeeping. In many cases, compliance with federal and state laws governing practices for controlled substances is the entry point for an investigation. Accordingly, ensuring compliance with these laws and regulations should be a top priority.

Providers should be prepared to demonstrate that their DEA registrations are current and appropriate for the services offered, and should be able to point to robust protocols regarding storage and inventory controls and prescribing standards. Even minor compliance risks in these areas can catch the attention of regulators, turning what was once a routine audit into a full-fledged investigation.  

Off-Label Use and FDA Risk

While ketamine is widely used in behavioral health treatment, the FDA has not approved ketamine for use in treatment for most of the conditions for which it is marketed. Recent federal attention to compounded ketamine—especially in at-home treatment models—suggests that regulators are paying closer attention to how these services are marketed to patients.

Even at the state level, regulators closely scrutinize marketing and promotional materials for content that has the potential to mislead prospective patients, including statements that imply FDA approval or exaggerate the safety, benefits, or efficacy of ketamine treatment.  

Patient Evaluation and Standard of Care

Regulators are increasingly focused on whether ketamine providers are meeting baseline clinical expectations, particularly given the drug’s known risks. Models that rely on limited evaluation or minimal supervision—including some telehealth and at-home approaches—are likely to face heightened scrutiny.

A compliance checklist should include a thorough review of the practice’s protocols for patient screening and eligibility determinations, informed consent, patient visit documentation standards, and patient monitoring during appointments. Without robust procedures in place, clinics can quickly find themselves under scrutiny for providing inappropriate patient care.  

Corporate Structure and CPOM Compliance

Many ketamine providers operate in states with corporate practice of medicine (CPOM) restrictions, which can create risk if ownership and management structures are not properly aligned with state law. While these issues are not generally the initial focus of an investigation, they can quickly snowball into greater issues once regulators take a closer look at the practice’s business model. Providers should closely review their business model to ensure clinical decision-making is appropriately insulated from any corporate ownership interests.

Marketing and Advertising Practices

Marketing remains one of the most visible and frequently scrutinized areas for ketamine providers. Specifically, regulators are increasingly focusing on claims regarding patient outcomes or success rates, patient testimonials, and representations about the safety and efficacy of ketamine treatment for certain conditions. Aggressive or unsupported marketing can quickly trigger scrutiny, particularly where claims appear inconsistent with clinical evidence.

Engaging legal counsel to review marketing materials before they are published ensures that you can grow your practice without inviting regulatory scrutiny.  

State Law and Licensing Risk

In practice, many enforcement actions are driven at the state level, particularly by state licensing boards. Findings that providers are operating outside their scope of practice, providing limited or no supervision of non-physician providers, or prescribing inappropriately can place providers on a fast track to disciplinary action, including loss of licensure.

Final Thoughts

Ketamine therapy sits at the intersection of controlled substance regulation, off-label prescribing, and emerging care delivery models—an area that is likely to remain under active and evolving scrutiny.

Providers that take a proactive approach to compliance by identifying risk areas and implementing appropriate safeguards will be in the best position to navigate this changing environment. Developing a structured compliance checklist is a practical first step toward building a model that can withstand increasing regulatory attention as expectations continue to develop.

Need help developing a compliance plan for your ketamine practice? We’ve got you covered. With years of combined experience from some of the nation’s largest health care companies, our attorneys are trusted compliance experts who have the insights you need to position your practice for success.